Canary Capital has revised its utility for a spot Solana ETF, signaling a extra formidable technique by integrating staking options into the product.
The amended submitting, lately submitted to the U.S. Securities and Alternate Fee (SEC), displays a rebranded title — now the Canary Marinade Solana ETF — and a newly fashioned partnership with Marinade Finance, a key participant within the Solana staking ecosystem.
The transfer marks a shift in ETF improvement as regulators slowly heat to the concept of staking integration, one thing beforehand excluded from Ethereum ETF proposals. Below the present SEC management, asset managers are discovering room to revisit earlier frameworks and construct out extra superior choices — particularly for altcoin-based funds.
Bloomberg analyst James Seyffart identified that the revised submitting highlights Marinade’s function in enabling native SOL staking inside the ETF construction. Marinade had beforehand hinted at a significant collaboration through social media, now confirmed with this up to date prospectus.
Nonetheless, regulatory readability stays elusive. The SEC lately delayed choices on a number of crypto ETF functions, together with these from 21Shares, Bitwise, and Canary itself. The following key deadline for Canary’s Solana ETF is August 17, with ultimate rulings for all SOL ETFs anticipated by October 10 — a timeline that mirrors the sample used for Bitcoin and Ethereum ETF approvals.
Seyffart believes the earliest window for a inexperienced mild might arrive in late Q2, however realistically expects choices to land in early This fall. In the meantime, prediction markets stay bullish. In keeping with Polymarket, there’s an 82% chance {that a} Solana ETF shall be accepted in 2025, although solely an 18% likelihood of it taking place earlier than the tip of July.
Including gas to that optimism, Bloomberg analysts now estimate a 90% likelihood of approval this yr, citing the SEC’s evolving view of Solana as a commodity and the existence of regulated SOL futures on the CME.